TELO Profile
Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, is dedicated to the development and commercialization of therapeutic treatments targeting human stem cells. The company is focused on addressing age-related inflammatory conditions and improving post-chemotherapy recovery through innovative small molecule therapies. Its lead product candidate, TELOMIR-1, is an oral in situ therapeutic intervention designed to combat conditions such as hemochromatosis and osteoarthritis. TELOMIR-1 works by interrupting and preventing interleukin-17 induced inflammatory pathways, offering a novel approach to managing chronic inflammation.
The company was initially known as Metallo Therapies Inc. but rebranded to Telomir Pharmaceuticals, Inc. on October 10, 2022, to better reflect its strategic focus on telomere biology and stem cell therapeutics. Founded in 2021, Telomir Pharmaceuticals is headquartered in Baltimore, Maryland, positioning itself in a region known for its rich biotechnology and pharmaceutical research environment. The company aims to leverage this strategic location to advance its research and development efforts.
Telomir Pharmaceuticals is committed to pioneering new treatments that harness the power of stem cells and telomere biology. By targeting the underlying mechanisms of age-related diseases and inflammatory conditions, the company seeks to develop therapies that not only alleviate symptoms but also address the root causes of these ailments. This approach has the potential to significantly improve the quality of life for patients suffering from chronic inflammatory diseases and those undergoing chemotherapy.
As a pre-clinical-stage company, Telomir Pharmaceuticals is actively engaged in rigorous research and development activities to bring its innovative therapies to market. The company collaborates with leading academic institutions and research organizations to advance its scientific discoveries and accelerate the development of its therapeutic pipeline. Through its focus on cutting-edge science and commitment to addressing unmet medical needs, Telomir Pharmaceuticals aims to become a leader in the field of regenerative medicine and stem cell-based therapies.
|
